Monitor Group: China wordt rond 2020 biowetenschappelijk centrum
Array
Vandaag heeft Monitor Group een nieuw rapport uitgegeven getiteld “China the Life Sciences Leader of 2020”, waarin staat beschreven hoe China op dit moment een goede uitgangspositie heeft om zich in de komende tien jaar te ontwikkelen tot de wereldleider op het gebied van biowetenschappelijke ontdekkingen en innovatie. In een periode waarin deze tak van sport wereldwijd wordt geconfronteerd met problemen zoals hoge kosten voor de goedkeuring van medicijnen, heeft China een strategie ontwikkeld voor doelgerichte overheidsinvesteringen via verschillende nationale en regionale programma´s. Monitor Group is een internationaal adviesbureau.
Engelstalig bericht:
China to Become Life Science Powerhouse by 2020: Monitor Group
Today Monitor Group, a global management consulting firm, released a new report, China, the Life Sciences Leader of 2020, finding that China is poised to become the global leader in life science discovery and innovation within the next decade.
At a time when the global life sciences and pharmaceutical industries are beset by major challenges, including patent cliffs, skyrocketing costs of drug approvals and failures in key trials for potentially landmark new drugs, China has developed a strategy of targeted government investments. Through a variety of national and regional programs, China is spending billions on a new health care “safety net,†encouraging the growth of life science parks and startups, financing the development of a high-quality research infrastructure and luring back tens of thousands of Western-educated Chinese researchers.
“In just a decade’s time — a short-term horizon in the life sciences field — China will not only be a significant engine of innovation, but has the potential to create a new model for advanced drug discovery,†said George Baeder, who runs Monitor’s China life science practice from his office in Shanghai and co-authored the report. “Other industries have repeatedly failed to anticipate how quickly China can adapt and impact the global playing field.†Baeder cautions that the pharmaceutical industry must now also pay attention.
Based on research and interviews with dozens of life science professionals in both the U.S. and China, the Monitor report finds that China‘s life sciences industry is today gathering a critical mass of highly-skilled talent, savvy and focused venture investors and growing government support as its market for drugs and medical devices escalates. China’s domestic market is expected to overtake Japan and become the world’s second drug market by 2015, and as global pharma firms are forced to slim down and cut research staffs, many now see China as a compelling destination to conduct cutting edge new research.
Among other findings, Monitor says that:
- At least 80,000 Western-trained PhDs in the life sciences have already returned to China to work in the industry or in academic institutes. The pace of repatriation of these highly-skilled scientists is likely to accelerate over the coming decade.
- China will unleash US$124 billion between 2009 and 2012 alone to build new municipal as well as county-level hospitals as part of its broad-based health care reform.
- An exclusive Monitor survey of Chinese life science professionals now working in the United States finds that fully two-thirds contemplate either returning to China for good or becoming “sea turtlesâ€â€”life science professionals who constantly circulate between China and the U.S. in pursuit of commercial and research opportunities. The report argues that such “sea turtles†and the “hybrid†firms they create will become important drivers of China’s life sciences innovation as the biggest pharma firms are forced to specialize on core strengths and reduce head counts in areas where they have not succeeded in creating new therapies.
The report also illustrates how key entrepreneurs, life science professionals and academics are developing innovative new models for pharmaceutical research and development in China, using Chinese-led clinical research organizations to fast-track their research in hopes of creating better drugs, more rapidly. The report also catalogues a series of risks and bottlenecks that could limit China’s advance, however, including the ability of state regulators to encourage innovation while also ensuring that Chinese-made drugs are of the highest quality.
China, the Life Sciences Leader of 2020, is the latest in a series of reports on the global impact of China across various industries. All reports are available at www.monitor.com.
About Monitor Group
Monitor Group works with the world’s leading corporations, governments and social sector organizations to drive growth on the issues that are most important to them. The firm offers a range of services –advisory, capability-building and capital services – designed to unlock the challenges of achieving sustained growth. Founded in 1983 by six entrepreneurs, including Harvard Business School Professor Michael Porter and Monitor’s current Chairman Mark Fuller, Monitor brings leading edge ideas, approaches and methods to bear on clients’ toughest problems and biggest opportunities. Headquartered in Cambridge, Massachusetts, the firm employs over 1,500 people in 22 countries worldwide. For more information, visit www.monitor.com.
